New FMLA Guidance Empowers Patients to Participate in Clinical Trials
New FMLA guidance now protects job security for patients participating in clinical trials, removing a major barrier to accessing innovative treatments.
How to Prepare for FDA-Mandated Clinical Diversity Action Plans (DAPs)
Understanding FDA’s Guidance on Diversity Action Plans (DAPs) is vital for health equity in clinical trials. As DAPs become mandatory, sponsors must adapt recruitment strategies for inclusivity.
3 in 4 surveyed patients show strong interest in replacing medications with both approved and experimental treatments.
This growing openness offers a valuable opportunity for sponsors and CROs to engage motivated participants if recruitment strategies are aligned with patient motivations and trust.
Why HCP outreach is so important for recruiting patients in rare disease
In rare disease trials, where patients are few and diagnosis is complex, trusted healthcare providers play a critical role in bridging the gap. This blog explores why HCP outreach is a powerful and often overlooked tool for patient recruitment, and how it can drive more qualified referrals and meaningful engagement.
Compensation norms create inequity in clinical trials
Exploring how compensation practices in clinical trials contribute to inequities and hinder diverse patient participation
FDA Prioritizes Patient-Reported Outcomes in Clinical Trials
Patient-reported outcomes can help optimize clinical trial design and improve study results.
